Pulmonary complications of intravenous drug abuse. Experience at an inner-city hospital. NLM AIDSLINE Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Pulmonary complications of intravenous drug abuse. Experience at an inner-city hospital.

Chest. 1988 Aug;94(2):251-3. Unique Identifier : AIDSLINE MED/88283234
O'Donnell AE; Pappas LS; Pulmonary Division, Georgetown University Hospital, Washington,; DC.

Abstract: Fifty-one intravenous drug abusers were evaluated by a pulmonary consultative team over a 22-month period at a large inner city hospital. The most common pulmonary complication was septic pulmonary embolism, seen in 12 patients (23.5 percent). Community-acquired pneumonia was diagnosed in ten patients (19.6 percent). Mycobacterium tuberculosis occurred in five patients (9.8 percent). Although 25 of 40 patients (63 percent) tested for human immunodeficiency virus antibody were positive, acquired immunodeficiency syndrome (AIDS) was present in only five patients (9.8 percent). Bronchoscopy was used to evaluate pulmonary infiltrates in 15 of 51 cases (29 percent). Common bacterial infections and tuberculosis remain the most frequently encountered pulmonary problems in drug abusers, despite the onset of the AIDS epidemic.
Keywords: Acquired Immunodeficiency Syndrome/ETIOLOGY Adult Female Hospitalization Human Lung Diseases/*ETIOLOGY Male Pleural Diseases/ETIOLOGY Pneumonia/ETIOLOGY Pulmonary Embolism/ETIOLOGY Respiratory Tract Infections/ETIOLOGY Substance Abuse/*COMPLICATIONS JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/etiologyadultfemalehospitalizationhumanlungdiseases/KWDetiologymalepleuraldiseases/etiologypneumonia/etiologypulmonaryembolism/etiologyrespiratorytractinfections/etiologysubstanceabuse/KWDcomplicationsjournalarticle
881130
M88B0559

Copyright © 1988 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .